JMS CO.,LTD. (7702) Stock Price

JMS (Japan Medical Systems Co., Ltd.) is primarily engaged in the manufacturing and sales of medical devices and pharmaceuticals. The company operates both domestically and internationally, and also provides related services for medical devices and pharmaceuticals. Domestically, JMS works in cooperation with J.O. Pharma to advance healthcare-related business operations.

Internationally, JMS maintains operations in Singapore, China, the Philippines, Germany, and other regions. Specifically, subsidiaries such as JMS Singapore PTE. LTD. and Dalian JMS Medical Instruments Co., Ltd. conduct business in their respective markets. Additionally, the company operates in parts of the United States, South Korea, Thailand, and China.

JMS Teijin Home Medical Care Co., Ltd., a domestic subsidiary and affiliated company, manages other business operations. JMS Teijin Home Medical Care Co., Ltd. was recently acquired and is positioned as an equity method affiliate. This acquisition further strengthens the company's business foundation.

JMS (Japan Medical Systems Co., Ltd.) is positioning itself for growth as a solution company that develops products and services to address challenges in healthcare settings. In its Medium-Term Management Plan 2027, formulated in 2024, the company has adopted the theme "Transformation and Challenge to Create the Future," with core strategies focused on reforming its revenue structure and advancing globalization.

The company is working to improve profitability and realize a sustainable society by strengthening its business portfolio and reinforcing its management foundation. In particular, it is concentrating on four key areas—infusion and nutrition, dialysis, surgical treatment, and blood and cell therapy—while accelerating medical digital transformation and global expansion to enhance corporate value.

JMS has set targets to achieve operating profit of 2.5 billion yen and ROIC of 3.5% by 2027. Rather than pursuing growth at all costs, the company is restructuring its business and product portfolio through selective focus and concentration, aiming for long-term improvement in corporate value.